Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHSINASDAQ:HTBXOTCMKTS:IGXTNASDAQ:MBRXOTCMKTS:QBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsHTBXHeat Biologics$2.38$2.07▼$10.85$61.05MN/A171,558 shs43,600 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AMBRXMoleculin Biotech$0.30-3.3%$0.82$0.25▼$4.71$4.41M1.571.90 million shs2.44 million shsQBIOQ Biomed$0.00$0.00$0.00▼$0.03N/A2.224,600 shs14,151 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-67.91%HTBXHeat Biologics0.00%0.00%0.00%0.00%0.00%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%MBRXMoleculin Biotech0.00%+16.93%-65.18%-67.81%-91.13%QBIOQ Biomed0.00%0.00%0.00%-50.00%+∞Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHSIGuardion Health SciencesN/AN/AN/AN/AN/AN/AN/AN/AHTBXHeat BiologicsN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech3.2776 of 5 stars3.52.00.00.04.01.71.3QBIOQ BiomedN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHSIGuardion Health Sciences 0.00N/AN/AN/AHTBXHeat Biologics 0.00N/AN/AN/AIGXTIntelGenx Technologies 0.00N/AN/AN/AMBRXMoleculin Biotech 3.00Buy$4.001,224.94% UpsideQBIOQ Biomed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QBIO, IGXT, HTBX, MBRX, and GHSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHSIGuardion Health Sciences$12.25M0.35$0.14 per share23.15$6.39 per share0.50HTBXHeat BiologicsN/AN/AN/AN/AN/AN/AIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/AQBIOQ Biomed$280KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHSIGuardion Health Sciences$160K$4.870.66∞N/A22.79%-73.69%-48.17%N/AHTBXHeat BiologicsN/AN/A0.00N/AN/AN/AN/AN/AN/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AMBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)QBIOQ Biomed-$2.05MN/A0.00∞N/AN/AN/AN/AN/ALatest QBIO, IGXT, HTBX, MBRX, and GHSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHSIGuardion Health Sciences$5.00155.28%N/A102.67%N/AHTBXHeat BiologicsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHSIGuardion Health SciencesN/A16.6816.59HTBXHeat BiologicsN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AMBRXMoleculin BiotechN/A1.351.35QBIOQ BiomedN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHSIGuardion Health Sciences20.21%HTBXHeat BiologicsN/AIGXTIntelGenx TechnologiesN/AMBRXMoleculin Biotech15.52%QBIOQ BiomedN/AInsider OwnershipCompanyInsider OwnershipGHSIGuardion Health Sciences1.32%HTBXHeat BiologicsN/AIGXTIntelGenx Technologies42.05%MBRXMoleculin Biotech1.90%QBIOQ Biomed28.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHSIGuardion Health Sciences101.35 million1.33 millionNot OptionableHTBXHeat Biologics4925.65 millionN/AOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableQBIOQ Biomed3N/AN/ANot OptionableQBIO, IGXT, HTBX, MBRX, and GHSI HeadlinesRecent News About These CompaniesQ BioMed IncApril 8, 2025 | uk.investing.comOrchestra Biomed Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comOrchestra BioMed Reports Q3 2024 Results, Advances Key Clinical ProgramsNovember 14, 2024 | msn.comIBM's newest 156-qubit quantum chip can run 50 times faster than its predecessor — equipping it for scientific researchNovember 14, 2024 | msn.comFormer Bigfoot Biomedical CEO takes corner office at AI medtech company Q-BioOctober 11, 2024 | massdevice.comA Powerful New Tool for Biomedical ResearchSeptember 12, 2024 | msn.comOpinion: Artificial intelligence already improving biomedical research, health careSeptember 5, 2024 | sandiegouniontribune.comSClearmind Biomedical wins FDA clearance for Neuroblade minimally invasive neuroendoscopy techAugust 27, 2024 | massdevice.comMayo Clinic taps startup SandboxAQ to study new tech — quantum sensing and AI — for cardiac diagnosticsAugust 8, 2024 | fiercehealthcare.comF18th Annual Q-Bio Conference: Global scholars explore new Frontiers in quantitative biologyAugust 7, 2024 | eurekalert.orgEE&Q Master Cordless Gutta Percha Obturator from Meta BioMedMarch 24, 2024 | news-medical.netNClearside Biomedical Q4 2023 Earnings PreviewMarch 11, 2024 | msn.comQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesFebruary 24, 2024 | benzinga.comBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesFebruary 13, 2024 | msn.comBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthJanuary 28, 2024 | msn.comQ BioMed Inc QBIONovember 16, 2023 | morningstar.comMBiomedical Sciences PhD ProgramNovember 13, 2023 | uwyo.eduUQ&A: How generative AI could help accelerate biomedical researchNovember 6, 2023 | phys.orgPQBIO Q BioMed Inc.August 18, 2023 | seekingalpha.comQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in EuropeApril 17, 2023 | pharmabiz.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQBIO, IGXT, HTBX, MBRX, and GHSI Company DescriptionsGuardion Health Sciences NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Heat Biologics NASDAQ:HTBXHeat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Moleculin Biotech NASDAQ:MBRX$0.30 -0.01 (-3.30%) As of 04:00 PM EasternMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Q Biomed OTCMKTS:QBIO$0.0001 0.00 (0.00%) As of 09:57 AM EasternQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.